Low-dose propranolol regimen for infantile haemangioma.

摘要: Aims Propranolol, now the preferred treatment for problematic proliferating infantile haemangioma (IH), at an empirical cardiovascular dosage of 2–3 mg/kg/day is associated with variable complication rates. A meta-analysis shows complications in 31% patients a mean 2.12 mg/kg/day. This study reports on minimal and duration to achieve accelerated involution side effects using stepwise escalation regimen. Methods Consecutive IH treated propranolol were identified from our vascular anomalies database. Propranolol was commenced 0.5 mg/kg/day two divided doses increased 1 mg/kg/day after 24 h. The reviewed 1 week, 1.5 mg/kg/day. further by 0.5 mg/kg/day, if necessary, involution. Results Forty-four patients, aged 3 weeks 11 months (mean, 3.8 months), received therapy IH. required 1.5–2 mg/kg/day. Treatment maintained average 9.3 discontinued age 14.2 months. Rebound growth occurred first patient this series when withdrawn 7.5 age, requiring reinstitution treatment. Slight rebound following cessation observed four other but not required. Minor three (6.8%) patients. Conclusions Propranolol 1.5–2 mg/kg/day, administered escalation, safe effective treating continued